(Press-News.org) For the first time, researchers have developed a form of the omega-3 fatty acid docosahexaenoic acid (DHA) that is capable of crossing into the eye’s retina to ward off visual declines related to Alzheimer’s disease, diabetes and other disorders.
The DHA found in fish oil capsules and other supplements is typically in a form called triacylglycerol (TAG) DHA. Although TAG-DHA has benefits in other parts of the body, it does not reach the eyes because it cannot travel from the bloodstream into the retina. For the study, researchers created a new lysophospholipid form of DHA, or LPC-DHA. In studies using mice, LPC-DHA successfully increased DHA in the retina and reduced eye problems associated with Alzheimer’s-like processes.
“Dietary LPC-DHA is enormously superior to TAG-DHA in enriching retinal DHA and could be potentially beneficial for various retinopathies in patients,” said Sugasini Dhavamani, a research assistant professor in the Department of Medicine at the University of Illinois at Chicago. “This approach provides a novel therapeutic approach for the prevention or mitigation of retinal dysfunction associated with Alzheimer’s disease and diabetes.”
Dhavamani will present the research at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, March 25–28 in Seattle.
In healthy eyes, DHA is concentrated in the retina, where it helps maintain photoreceptors, the cells that convert light into signals that are sent to the brain. DHA deficiency in the retina is associated with vision loss. People with Alzheimer’s disease, as well as those with diabetes, retinitis pigmentosa, age-related macular degeneration and peroxisomal disorders, frequently have abnormally low levels of retinal DHA, and visual impairments are common as a result.
While boosting DHA can help to prevent such declines, increasing retinal DHA content has been challenging with currently available supplements. For a dietary supplement to deliver DHA to the retina, the DHA must be able to first be absorbed from the intestine into the bloodstream and then cross from the bloodstream into the retina.
“Increasing the retinal DHA at clinically feasible doses has not been possible until now because of the specificity of the blood–retinal barrier that is incompatible with the specificity of the intestinal barrier,” said Dhavamani. “This study uses the novel approach of dietary LPC-DHA that overcomes both intestinal and blood–retinal barriers and improves retinal function.”
The researchers tested their LPC-DHA supplement in mice bred to exhibit processes similar to those found in early-onset Alzheimer’s disease. After six months, mice that were fed LPC-DHA daily showed a 96% improvement in retinal DHA content as well as preserved retinal structure and function. In contrast, TAG-DHA supplements had no effect on retinal DHA levels or function.
The results suggest that LPC-DHA supplements could help to prevent Alzheimer’s-related declines in visual function. Researchers say the approach should also be helpful for other disorders in which DHA deficiency and vision impairment are common.
The dosage of LPC-DHA used in the study is equivalent to about 250 to 500 milligrams of omega-3 fatty acids per day in humans. Since these studies were conducted in mice, further studies would be needed to confirm that LPC-DHA is safe and effective for use in humans.
Sugasini Dhavamani will present this research during the Spotlight Session on Chemical biology of natural products, nucleic acids and small molecules from 3:15–4:15 p.m. PDT on Monday, March 27, in Rooms 602–604 of the Seattle Convention Center (abstract). Contact the media team for more information or to obtain a free press pass to attend the meeting.
Image available.
This work was supported by an Alzheimer’s Association Research Grant (AARG).
About the American Society for Biochemistry and Molecular Biology (ASBMB)
The ASBMB is a nonprofit scientific and educational organization with more than 12,000 members worldwide. Founded in 1906 to advance the science of biochemistry and molecular biology, the society publishes three peer-reviewed journals, advocates for funding of basic research and education, supports science education at all levels, and promotes the diversity of individuals entering the scientific workforce. www.asbmb.org
Find more news briefs and tipsheets at: https://discoverbmb.asbmb.org/newsroom.
###
END
The lower prevalence of ‘risky’ sex—with multiple or new partners without using condoms—which occurred during the early stages of the COVID-19 pandemic, was still evident a year after Britain’s first lockdown, reveal the results of a major national survey, published online in the journal Sexually Transmitted Infections.
While there were fewer reported unplanned pregnancies and abortions than indicated by a comparable survey a decade earlier, there were significantly higher prevailing levels of sexual dissatisfaction and worries ...
People with atopic (allergic) diseases like asthma or eczema may be at heightened risk of the painful and often disabling joint condition, osteoarthritis, finds research published online in the Annals of the Rheumatic Diseases.
Drugs used to dampen down the physiological prompts for allergic reactions in the body may help lessen this risk, suggest the researchers.
Osteoarthritis is the most common form of arthritis. But despite the high prevalence, substantial costs, and debilitating impact of the disease, there is as yet no effective ...
Engaging communities in developing a real-time early warning system could help to reduce the often-devastating impact of flooding on people and property – particularly in mountainous regions where extreme water events are a ‘wicked’ problem, a new study reveals
Flash floods are becoming more frequent and damaging to the lives and property of vulnerable people, but researchers believe that using a SMART approach to engage with those living in such areas will help to better signal impending risk from flooding.
Scientists believe that combining meteorological data with information on how people live and work in such regions, will help disaster risk ...
For the first time, researchers have identified specific regions of the brain that are damaged by high blood pressure and may contribute to a decline in mental processes and the development of dementia.
High blood pressure is known to be involved in causing dementia and damage to brain function. The study, which is published in the European Heart Journal [1] today (Tuesday), shows how this happens. It gathered information from a combination of magnetic resonance imaging (MRI) of brains, genetic analyses and observational data from thousands of patients to look at the effect of high blood pressure on cognitive function. The researchers then checked their findings ...
Growing concerns over the potential health effects of exposure to phthalates, a component of many plastics and also known as a plasticizer, have led to a search for safer alternatives. In a new study conducted in cell cultures, researchers found that the chemical acetyl tributyl citrate (ATBC) might not be the best replacement because it appears to interfere with the growth and maintenance of neurons.
“In the past, industries have promptly shifted away from the usage of toxic chemicals only to produce an equally toxic chemical, so this is something we are actively trying to avoid repeating,” said Kyle Sease, a graduate student at Central Washington ...
A new study found that people who are currently suffering or face a high risk of post-traumatic stress disorder show particular patterns in four biomarkers measurable with a simple blood test. The findings suggest these biomarkers could be used to predict a person’s likelihood of developing PTSD, diagnose the disorder or monitor the response to treatment.
PTSD can occur after experiencing or witnessing a traumatic event. It is currently diagnosed based on symptoms such as flashbacks, difficulty sleeping or concentrating, ...
M1 and M2 are activated macrophages that protect our immune system and maintain homeostasis. Interestingly, they are characterized by distinct and opposing phenotypes. M1 macrophages are known for their bactericidal and tumoricidal properties by secreting pro-inflammatory cytokines, while M2 macrophages facilitate immunosuppressive responses and help cancer progression. As such, reprogramming macrophages from M2 to M1 phenotype has been regarded as a significant interest in the view of potential cancer ...
People reveal more personal information when you ask them the same questions a second time – according to new research from the University of East Anglia.
A new study published today reveals how simple repetition can make people over-disclose, and potentially put themselves at risk of identity theft and cyber crime.
The research team say that understanding why people disclose personal data could help inform measures to address the problem.
From subscribing to online newspapers to completing customer surveys, our personal data is being mined continuously; the world’s most valuable resource is no longer oil, but data.
But for consumers who provide their personal ...
In February of this year, Graphene Flagship associated member Graphenest and manufacturing company Hubron International entered a new strategic partnership. Their shared aim is to explore the development and commercialization of graphene-based polymer masterbatch and compounds with unprecedented electromagnetic interference (EMI) shielding performance for electronic enclosures manufacturing.
This new product line will start with a graphene-based thermoplastic suitable to be implemented as a remarkable EMI shielding solution in medium-high and high frequencies (for 5G and beyond).
The agreement brings together Graphenest’s knowledge around graphene ...
A new drug combination for men with advanced prostate cancer has shown sustained increase in survival rates.
The results from the clinical trial of ENZAMET, co-chaired by Professor Christopher Sweeney, Director of the South Australian immunoGENomics Cancer Institute (SAiGENCI) that operates within the University of Adelaide, have been published today in The Lancet Oncology.
For people with metastatic hormone-sensitive prostate cancer, the addition of an androgen receptor blocker with enzalutamide ...
